Assessment on Antihypertensive Effect and Safety of Nifedipine Controlled-Release Tablet Administered at 80 mg/day in Practical Clinic

REFERENCES

• Committee on guidelines for the management of hypertension, Japanese Society of Hypertension, Guidelines for Hypertension 2009, Tokyo: The Japanese Society of Hypertension, 2009.
   Google Scholar
• Ohkubo T, Obara T, Funahashi J, . Control of blood pressure as measured at home and office, and comparison with physicians’ assessment of control among treated hypertensive patients in Japan: first report of the Japan home versus office blood pressure management evaluation (J-HOME) study. Hypertens Res 2004; 27:755–763.
   Google Scholar
• Nakamichi N, Yanagida T, Hikima Y, . A phase I clinical trial of nifedipine controlled-release formulation (BAY a 1040-OD tablet): a single-dose study. Jpn Pharmacol Ther 1995; 23(Suppl. 2):s241–s255.
   Google Scholar
• Nakamichi N, Yanagida T, Hikima Y, . A phase I clinical trial of nifedipine controlled-release formulation (BAY a 1040-OD tablet): a repeated-dose study. Jpn Pharmacol Ther 1995; 23(Suppl. 2):s257–s269.
   Google Scholar
• Landmark K. Antihypertensive and metabolic effects of long-term therapy with nifedipine controlled release tablets. J Cardiovasc Pharmacology 1985; 7:12–17.
   Google Scholar
• Aoki K, Yamashita K, Suzuki A, Takikawa K, Hotta K. Uptake of calcium ions sarcoplasmic reticulum from heart and arterial smooth muscle in the spontaneously hypertensive rat (SHR). Clin Exp Pharmacol Physiol 1976; 3(Suppl.):27–30.
   Google Scholar
• Aoki K, Kawaguchi Y, Sato K, Kondo S, Yamamoto M. Clinical and pharmacological properties of calcium antagonista in essential hypertension in humans and spontaneously hypertensive rats. J Cardiovasc Pharmacol 1982; 4:s298–s302.
   Google Scholar
• Minami J, Numabe A, Andoh N, . Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension. Br J Clin Pharmacol 2004; 57:632–639.
   Google Scholar
• Sato H, Arai H, Fukuda E, . Effects of nifedipine retard on heart rate and autonomic balance in patients with ischemic heart disease. Int J Clin Pharmacol Res 2001; 21:65–71.
   Google Scholar
• Bayer Yakuhin, Ltd. Medical Affairs & Pharmacovigilance, Assessment on safety and efficacy of nifedipine controlled-release tablet (Adalate CR tablet) in patients with uncontrolled hypertension -a specific use survey. J New Rem & Clin 2010; 59:1859–1880.
   Google Scholar
• Horio T, Iwashima Y, Yoshihara F, . Percentage of patients achieving target goal for clinic and home blood pressures in treated hypertensive outpatients in assessment based on the criteria from JSH2009 guidelines, The annual meeting of the Japanese Society of Hypertension; AB 198, Otsu, Japan, October 1–3, 2009.
   Google Scholar
• Kaplan NM, Flynn JT, eds. Treatment of hypertension. In: Kaplan’s Clinical Hypertension, 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006, 217–310.
   Google Scholar
• Bakris GL, Williams M, Dworkin L, . Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646–661.
   Google Scholar
• JATOS study group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31:2115–2127.
   Google Scholar
• Fujiwara T, Ii Y, Hatsuzawa J, . The phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily. J Hum Hypertens 2009; 23:521–529.
   Google Scholar
• Ito M, Miyakawa M, Yoshida K, Uchiba K. Assessment on the antihypertensive effect of an increased dose of amlodipine at 10 mg/day – a report from a retrospective observational study. Prog Med 2010; 30:1391–1397 (in Japanese).
   Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002; 288:2981–2997.
   Google Scholar
• Julius S, Kjeldsen SE, Weber M, . For the VALUE trial group: outcomes in hypertensive patients at high cardiovascular risk treated with regimen based on valsartan or amlodipine; the VALUE randomized trial. Lancet 2004; 363:2022–2031.
   Google Scholar
• Nissen SE, Tuzcu EM, Libby P, . For the CAMELOT investigators: effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 2004; 292:2217–2225.
   Google Scholar
• Brown MJ, Palmer CR, Castaigne A, . Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a GOAL in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366–372.
   Google Scholar
• Poole-Wilson PA, Lubsen J, Kirwan BA, . Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 2004; 364:849–857.
   Google Scholar
• Miyakawa M. Treatment of early-morning hypertension using original dosing schedule- comparison of calcium antagonists as a optimal agent for combination therapy with ARB. Blood Press 2008; 15:1089–1094.
   Google Scholar
• Saito I, Saruta T. ADVANCE-Combi Study Group. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res 2006; 29:789–796.
   Google Scholar
• Bayer Yakuhin, Ltd. Medical affairs & pharmacovigilance: drug special investigation of nifedipine controlled release tablet (Adalat CR); efficacy and safety of nifedipine CR in refractory hypertension. J New Rem Clin 2010; 59:1859–1862.
   Google Scholar